Screening and Monitoring for Infectious Complications When Immunosuppressive Agents Are Studied in the Treatment of Autoimmune Disorders.
Significant progress has been made in the development, investigation, and clinical application of immunosuppressive agents to treat a variety of autoimmune disorders. The expansion of clinical applications of these new agents requires the performance of large multicenter clinical trials. These large clinical trials are particularly important as one considers these agents for the treatment of type 1 diabetes, which although autoimmune in its pathogenesis, is not classically treated as an autoimmune disorder. Although these agents hold promise for amelioration or cure of this disease, they have the potential to facilitate infectious complications. There are limited data regarding the prospective assessment of infectious risks with these agents in trials of this nature. Pediatric subjects may be at greater risk due to the higher likelihood of primary infection. A subgroup of experts associated with TrialNet (a National Institutes of Health [NIH]-funded Type 1 diabetes mellitus research network) with expertise in infectious diseases, immunology, and diagnostics developed an approach for screening and monitoring of immunosuppression-associated infections for prospective use in clinical trials. The goals of these recommendations are to provide a structured approach to monitor for infections, to identify specific laboratory testing and surveillance methods, and to consider therapies for treatment of these potential complications. Prospective evaluations of these infectious risks allow for greater scientific rigor in the evaluation of risk, which must be balanced with the potential benefits of these therapies. Our experience supports an important role for investigators with expertise in infections in immunocompromised individuals in protocol development of immunosuppressive trials in type 1diabetes and potentially other autoimmune diseases.
Children's National Medical Center, Washington, District of Columbia ; The George Washington University, District of Columbia.
Brett J
BJ
Loechelt
Children's Hospital of Pittsburgh, Pennsylvania.
Michael
M
Green
University of Colorado Anschutz Medical Center, Aurora.
Peter A
PA
Gottlieb
Perelman School of Medicine of the University of Pennsylvania, Philadelphia.
Emily
E
Blumberg
University of Colorado Anschutz Medical Center, Aurora.
Adriana
A
Weinberg
The George Washington University, District of Columbia.
Scott
S
Quinlan
Brigham and Women's Hospital/Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Lindsey R
LR
Baden
D001327:Autoimmune Diseases / Q000150:complications* / Q000188:drug therapy; D002986:Clinical Trials as Topic / Q000592:standards; D003141:Communicable Diseases / Q000188:drug therapy / Q000209:etiology*; D006801:Humans; D016867:Immunocompromised Host; D007165:Immunosuppression Therapy / Q000592:standards; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D009894:Opportunistic Infections / Q000209:etiology
D007166:Immunosuppressive Agents
clinical trials; immunosuppressive agents; infectious complications